-
Mashup Score: 0Adjuvant Everolimus Plus Standard ET Does Not Significantly Improve iDFS or OS in HR+ Breast Cancer - 1 year(s) ago
Mariana Chavez-MacGregor, MD, MSC, Chavez-MacGregor discussed key efficacy and safety data from the SWOG 1207 trial of adjuvant everolimus in postmenopausal patients with high-risk, hormone receptor–positive breast cancer.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Updates From 2022 SABCS Underscore the Continued Expansion of Treatment Options in Metastatic Breast Cancer - 1 year(s) ago
Virginia F. Borges, MD, MMSc, and colleagues highlight updates across the breast cancer landscape, including key updates from the 2022 SABCS.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Virginia F. Borges, MD, MMSc, and colleagues highlight updates across the breast cancer landscape, including key updates from the 2022 SABCS. @YoungWomenBC @CUCancerCenter #SABCS2022 #bcsm https://t.co/FSpZzu69cJ
-
-
Mashup Score: 0Updates From 2022 SABCS Underscore the Continued Expansion of Treatment Options in Metastatic Breast Cancer - 1 year(s) ago
Virginia F. Borges, MD, MMSc, and colleagues highlight updates across the breast cancer landscape, including key updates from the 2022 SABCS.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Updates From 2022 SABCS Underscore the Continued Expansion of Treatment Options in Metastatic Breast Cancer @YoungWomenBC @CUCancerCenter @SABCSSanAntonio @OncLiveSOSS #SABCS2022 #OncLiveIPC #bcsm https://t.co/m0264QevGG
-
-
Mashup Score: 0
John Crown, MB, BCh, BAO, BSc, MD, MBA, discusses previous research with anti-HER2 TKIs in HER2-positive breast cancer, expanded on key follow-up data from this phase 2 trial, and emphasized the importance of continued investigation into this underutilized combination.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Neoadjuvant Anti-HER2 TKIs Require Further Investigation for HER2+ Breast Cancer @ProfJohnCrown @DCU @CancerIreland_ @SABCSSanAntonio #SABCS2022 #bcsm https://t.co/WHZ11oiwzy
-
-
Mashup Score: 2Real-World Analysis Shows Low Use of Ovarian Suppression in Premenopausal HR+/HER2+ Breast Cancer - 1 year(s) ago
Maryam Lustberg, MD, MPH, discusses key results from a retrospective analysis of ovarian suppression in HR–positive, HER2-positive breast cancer, the importance of assessing real-world practice patterns, and the need for continued study of other predictive biomarkers for endocrine therapy in this population.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Real-World Analysis Shows Low Use of Ovarian Suppression in Premenopausal HR+/HER2+ Breast Cancer @maryam_lustberg @YaleCancer @SABCSSanAntonio #SABCS2022 #bcsm https://t.co/CE45jzLJzK
-
-
Mashup Score: 5DESTINY-Breast04 Subgroup Analysis Confirms Trastuzumab Deruxtecan Benefit in HER2-low Metastatic Breast Cancer - 1 year(s) ago
Patient history and disease characteristics did not affect outcomes for patients with metastatic HER2-low breast cancer who received fam-trastuzumab deruxtecan-nxki in the DESTINY-Breast04 study.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
DESTINY-Breast04 Subgroup Analysis Confirms Trastuzumab Deruxtecan Benefit in HER2-low Metastatic Breast Cancer @SABCSSanAntonio #SABCS22 #SABCS2022 #bcsm https://t.co/cQrxR8GWid
-
-
Mashup Score: 0A Review of the 2022 SABCS Twitter Takeover - 1 year(s) ago
During the 2022 San Antonio Breast Cancer Symposium, Neil M. Iyengar, MD, took over the CancerNetwork® Twitter to review key presentation takeaways.
Source: Cancer NetworkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
During the 2022 San Antonio Breast Cancer Symposium, Neil M. Iyengar, MD, took over the CancerNetwork® Twitter to review key presentation takeaways. #bcsm #SABCS2022 | @SABCSSanAntonio @Neil_Iyengar @MSKCancerCenter https://t.co/eRZdJwbY4w
-
-
Mashup Score: 0Efficacy of Sacituzumab Govitecan in TROPiCS-02 Trial Not Dependent on Trop-2 Expression - The ASCO Post - 1 year(s) ago
By Caroline Helwick Posted: 12/11/2022 11:19:00 AM Last Updated: 12/11/2022 11:24:24 AM The latest analysis of the TROPiCS-02 breast cancer trial shows that sacituzumab govitecan-hziy is effective in patients with a wide range of Trop-2 expression levels. The findings were reported at the 2022 San Antonio…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Efficacy of Sacituzumab Govitecan in TROPiCS-02 Trial Not Dependent on Trop-2 Expression https://t.co/IdWxY5kZDa #bcsm #breastcancer #oncology #SABCS22 #SABCS2022 @SABCSSanAntonio
-
-
Mashup Score: 2Per Karlsson New Data on Breast-Conserving Surgery With or Without Radiotherapy - The ASCO Post - 1 year(s) ago
2022 San Antonio Breast Cancer Symposium Per Karlsson, MD, PhD, of Sweden’s University of Gothenburg and the Sahlgrenska Comprehensive Cancer Center, discusses results from the POLAR study, which was a meta-analysis of three clinical trials of breast-conserving surgery with or without radiotherapy. POLAR is the first genomic classifier that appears not only to be prognostic for…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Per Karlsson, MD, PhD: New data on breast-conserving surgery, with or without radiotherapy https://t.co/jDDmqkZfrE #SABCS22 #SABCS2022 #oncology #bcsm #breastcancer @SahlgrenskaAcad @goteborgsuni
-
-
Mashup Score: 1
By Caroline Helwick Posted: 12/11/2022 10:35:00 AM Last Updated: 12/11/2022 10:43:45 AM Results of a planned interim overall survival analysis of the phase III monarchE trial offer further support for the addition of abemaciclib to adjuvant endocrine therapy for patients with hormone receptor–positive,…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
MonarchE Update: Benefit of Abemaciclib Increases Over Time https://t.co/vO2ytK5qxm #SABCS22 #SABCS2022 #breastcancer #bcsm #oncology @SABCSSanAntonio
-
Adjuvant Everolimus Plus Standard ET Does Not Significantly Improve iDFS or OS in HR+ Breast Cancer @MDAndersonNews #SABCS2022 #bcsm https://t.co/rraYUILZrY